In July 2015, Neurotherapeutics published an article about Autism spectrum disorder (ASD), presenting a modern view of the endocannabinoid (eCB) system, and alterations of its main components in human patients and animal models relevant to ASD. Our understanding of eCB signaling in autism is still in its infancy compared with other disorders of the central nervous system or of peripheral tissues, where eCB-based therapies have already reached preclinical and clinical phases. However, research in this field is rapidly evolving, and novel drugs able to hit specifically a distinct element of the eCB system are being developed at a surprising speed. Read More
Published in 2012, this study concluded that elevation of cannabinoid receptor activity either by pharmacological blockade of the degradation of cannabinoids or by receptor agonists could be a promising strategy for slowing down the progression of brain aging and for alleviating the symptoms of neurodegenerative disorders.
Endocannabinoid Anandamide and Breast Cancer – more evidence. This 2014 study out of Italy, published in the journal Translational Medicine, found that following anandamide treatment, MDA-MB-231 cells lose their ability to stimulate endothelial cells proliferation in vitro, due to a significant inhibition of all the pro-angiogenic factors produced by these cells. This finding adds another piece of evidence to the anti-tumor efficacy of anandamide in breast cancer. Read More
Published in the July 2014 issue of Translational Psychiatry, this study out of Vanderbilt University provides support that endocannabinoid augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders.
This 2004 study by Ethan Russo, published in the journal Neuroendocrinology, examines the concept of clinical endocannabinoid deficiency and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis. Read More
This 2014 study out of Japan indicated that genetic traits, specifically the CB1 receptor gene genotypes, are closely related to happiness. C allele carriers of the SNP of CNR1 who are sensitive to positive emotional stimuli may experience a higher magnitude pleasure response when they experience positive events and may have a higher subjective happiness level. Read More
Results from a 2005 study out of Spain, published in the Journal of Neuroscience, indicate that cannabinoid receptors are important in the pathology of Alzheimer’s Disease and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease. Read More
In a 2013 issue of the journal Nutrition & Metabolism, four drugs (ethanol, caffeine, nicotine & THC) were evaluated for their effect on exercise metabolism. Overall, it appears that cannabis does not have ergogenic potential in sports activities and thus, its inclusion on the banned list is likely a function of its illicitness. Read More
Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review published in 2008 in the Journal of British Pharmacology focuses on the manner with which three of these compounds, (_)-trans-D9-tetrahydrocannabinol (D9-THC), (_)-cannabidiol (CBD) and (_)-trans-D9-tetrahydrocannabivarin (D9-THCV), interact with cannabinoid receptors CB1 and CB2. Read More